Klinische Wochenschrift

, Volume 65, Issue 8, pp 380–386 | Cite as

Intralymphatic interleukin-2 treatment of a hemophiliac AIDS patient with defective interleukin-2 production

  • M. Gramatzki
  • G. R. Burmester
  • N. Heyder
  • H. G. Nüßlein
  • W. Rödl
  • W. Grote
  • D. A. Monner
  • P. F. Mühlradt
  • J. R. Kalden
Kasuistiken

Summary

To improve immune functions in an interleukin-2 (IL-2) deficient hemophiliac AIDS patient suffering from severePneumocystis carinii pneumonia, treatment with IL-2 was started in addition to standard antimicrobioal therapy. Highly purified IL-2 was administered subcutaneously and then repeatedly intralymphatically in a manner similar to pedal lymphography. No toxicity was observed. The patient temporarily improved clinically as well as with regard to immunological functions. Particularly the in vitro response to phytohemagglutinin (PHA) could partly be restored, and skin tests revealed improved response to recall antigens. These findings indicate that IL-2 can be administered safely and effectively by the intralymphatic route and may — in addition to antibiotics — be of value in AIDS patients with severe opportunistic infections.

Key words

Interleukin-2 Intralymphatic treatment AIDS Pneumocystis carinii pneumonia Immune response 

Abbreviations

AIDS

Acquired immunodeficiency syndrome

ConA

Concanavalin A

CTC

Cultured T cells

IL-2

Interleukin-2

K cells

Killer cells

NK cells

Natural killer cells

PHA

Phytohemagglutinin

PBMC

Peripheral blood mononuclear cells

PWM

Pokeweed mitogen

TMP-SMZ

Trimethoprim-sulfamethoxazole

TPA

12-0-Tetradecanoyl-phorbol-13-acetate

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abo T, Balch CM (1981) A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol 127:1024–1028Google Scholar
  2. 2.
    Bödecker BGD, Lehmann J, van Damme J, Kappmeyer H, Gassel WD, Havemann K, Schwulera V, Rühl F, Mühl F, Mühlradt PF (1984) Production of five human lymphokines (granulocyte-macrophage colony stimulating factor, interferon-γ, interleukin-2, macrophage cytotoxicity factor, and macrophage migration inhibitory factor) from ConA stimulated lymphocyte cultures in bioreactors. Immunobiol 166:12–23Google Scholar
  3. 3.
    Burmester GR, Yu DTY, Irani AM, Kunkel HG, Winchester RJ (1981) Ia+ cells in synovial fluid and tissues of patients with rheumatoid arthritis. Arthritis Rheum 24:1370–1376Google Scholar
  4. 4.
    Centers for Disease Control (1982)Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR 31:365–367Google Scholar
  5. 5.
    Ciobanu N, Welte K, Kruger G, Venuta S, Gold J, Feldmann SP, Wang CJ, Koziner B, Moore MAS, Safai B, Mertelsmann R (1983) Defective T cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin-2. J Clin Immunol 3:332–340Google Scholar
  6. 6.
    Donohue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203–2208Google Scholar
  7. 7.
    Dopfer R, Niethammer D, Peter HH, Kniep EM, Monner DA, Mühlradt PF (1984) In vivo effects of interleukin-2 on lymphocyte subpopulations in a patient with severe combined immunodeficiency. Immunobiology 167:452–461Google Scholar
  8. 8.
    Fauci AS, Macher AM, Longo DL, Lane HC, Rook AH, Masur H, Gelmann EP (1984) Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic and therapeutic considerations. Ann Int Med 100:92–106Google Scholar
  9. 9.
    Flomenberg N, Welte K, Mertelsmann R, Kernan MN, Ciobanu N, Venuta S, Feldman S, Kruger G, Kirkpatrick D, Dupont B, O'Reilly R (1983) Immunologic effects of interleukin-2 in primary immunodeficiency disease. J Immunol 130:2644–2650Google Scholar
  10. 10.
    Gottlieb MS, Schroff R, Schanker HM, Weismann JD, Fan PT, Wolf RA, Saxon A (1981)Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. Evidence for new acquired immunodeficiency. N Engl J Med 305:1425–1431Google Scholar
  11. 11.
    Gramatzki M, Dolan MF, Fauci AS, Maples JA, Bonnard GD, Strong DM (1982) Immunologic characterization of a helper T cell lymphoma. Blood 59:702–708Google Scholar
  12. 12.
    Gramatzki M, Strong DM, Grove SB, Bonnard GD (1982) Cryopreserved human cultured T cells as responder cells for the quantitative measurement of interleukin-2: improvement of the assay. J Immunol Methods 53:209–220Google Scholar
  13. 13.
    Gramatzki M, Bonnard GD, Herbermann RB, Strong DM (1985) Characterization of cell lines enhancing IL-2 production by human PHA stimulated lymphocytes. Cell Immunol 90:142–153Google Scholar
  14. 14.
    Haynes BF, Hemler ME, Mann DL, Eisenbarth GS, Shelhamer J, Mostowski HS, Thomas CA, Strominger JL, Fauci AS (1981) Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 126:1409–1414Google Scholar
  15. 15.
    Kamoun M, Martin PJ, Hansen JA, Brown MA, Siudak AW, Nowinski RC (1981) Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med 153:207–212Google Scholar
  16. 16.
    Kniep EM, Kniep B, Grote W, Conradt HS, Manner DA, Mühlradt PF (1984) Purification of the T lymphocyte growth factor interleukin-2 from culture media of human peripheral blood leukocytes (buffy coats). Eur J Biochem 143:199–203Google Scholar
  17. 17.
    Kung PC, Talle MA, DeMaria ME, Butler MS, Lifter J, Goldstein G (1980) Strategies for generating monoclonal antibodies defining human T-lymphocyte differentiation antigens. Transplant Proc 12: [Suppl 1]:141–146Google Scholar
  18. 18.
    Leibold W, Bridge S (1979)75Se-release: a short and long term assay system for cellular cytotoxicity. Immunobiology 155:287–311Google Scholar
  19. 19.
    Leonard WJ, Depper JM, Uchiyma T, Waldmann TA, Greene WC (1982) A monoclonal antibody that appears to recognize the receptor for human T cell growth factor; partial characterization of the receptor. Nature 300:267–269Google Scholar
  20. 20.
    Lifson JD, Benike CJ, Mark DF, Koths K, Engleman EG (1984) Human recombinant interleukin-2 partly reconstitutes deficient in-vitro immune responses of lymphocytes from patients with AIDS. Lancet I:698–702Google Scholar
  21. 21.
    Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin-2. I. Half-life and immunologic effects of the Jurkat cell line derived interleukin-2. J Immunol 134:157–166Google Scholar
  22. 22.
    Masur H, Michelis MA, Greene JB, Onorato I, Vande Stouwe RA, Holzman RS, Wormser G, Brettman L, Lange M, Murray HW, Cunningham-Rundles S (1981) An outbreak of community acquiredPneumocystis carinii pneumonia — initial manifestation of cellular immune dysfunction. N Engl J Med 305:1431–1438Google Scholar
  23. 23.
    Mertelsmann R, Welte K (1984) Human interleukin-2. Clin Immunol Allergy 4:393–413Google Scholar
  24. 24.
    Mühlradt PF, Opitz HG (1982) Clearance of interleukin-2 from the blood of normal and T cell-depleted mice. Eur J Immunol 983–985Google Scholar
  25. 25.
    Rivin BE, Monroe JM, Hubschmann BP, Thomas PA (1984) AIDS outcome: a first follow up. N Engl J Med 311–857Google Scholar
  26. 26.
    Rook AH, Masur H, Lane C, Frederick W, Kasahara T, Macher AM, Djeu JY, Manischewitz JF, Jackson L, Fauci AS, Quinnan GV (1983) Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 72:398–403Google Scholar
  27. 27.
    Sheridan JF, Aurelian L, Donnenberg AD, Quinn TC (1984) Cell-mediated immunity to cytomegalovirus (CMV) and herpes simplex virus (HSV) antigens in the acquired immune deficiency syndrome: interleukin-1 and interleukin-2 modify in vitro responses. J Clin Immunol 4:304–311Google Scholar
  28. 28.
    Shevach EM, Herberman RB, Frank MM, Green I (1972) Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. J Clin Invest 51:1933–1938Google Scholar
  29. 29.
    Stashenke P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte specific antigen. J Immunol 125:1678–1685Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • M. Gramatzki
    • 1
  • G. R. Burmester
    • 1
  • N. Heyder
    • 2
  • H. G. Nüßlein
    • 1
  • W. Rödl
    • 2
  • W. Grote
    • 3
  • D. A. Monner
    • 3
  • P. F. Mühlradt
    • 3
  • J. R. Kalden
    • 1
  1. 1.Institut für Klinische ImmunologieUniversität Erlangen-NürnbergErlangen
  2. 2.Medizinische KlinikUniversität Erlangen-NürnbergErlangen
  3. 3.Gesellschaft für Biotechnologische Forschung mbH.Braunschweig

Personalised recommendations